Diclofenac mitigates virulence of multidrug-resistant Staphylococcus aureus

Abbas, Hisham A.; Atallah, Hamada; El-Sayed, Mostafa A.; El-Ganiny, Amira M.

doi:10.1007/s00203-020-01992-y

Cited by 28 publications

(45 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Pseudomonas aeruginosa Soheili et al, 2015;Belfield et al, 2017;Fourie et al, 2017;Ulusoy et al, 2017;Pereira et al, 2018;She et al, 2018;Abidi et al, 2019;Dai et al, 2019;Gerner et al, 2020 Staphylococcus aureus Belfield et al, 2017;Dotto et al, 2017;Xu et al, 2017;Cai et al, 2018;Oliveira et al, 2019;Abbas et al, 2020;Tzeng et al, 2020 Candida spp. Rosato et al, 2016;Fourie et al, 2017;Brilhante et al, 2020;Lin et al, 2020;Santos et al, 2020 Escherichia coli Cattò et al, 2017;Pereira et al, 2018;Leão et al, 2020…”

Section: Biofilm-forming Pathogen Number Of Experimental Studiesunclassified

“…Although there is evidence pointing to the activity of NSAIDs against S. aureus biofilms and other anti-virulence properties (e.g., inhibition of hemolysis and staphyloxanthin production; Abbas et al, 2020 ), most of these data were generated by in vitro studies using control laboratory bacterial strains, which may not necessarily indicate that these observations will be translated in vivo . These findings could also not be extrapolated to infections caused by different clonal complexes, given their significant differences in biofilm phenotypes ( Vanhommerig et al, 2014 ).…”

Section: Antibiofilm Activity Of Nsaids Against Staphylococcus Aureus and Selected Pathogenic Gram-negative Speciesmentioning

confidence: 99%

“…However, although the available in vitro data can create some enthusiasm on the prospects of repurposing NSAIDs as antibiofilm agents, these observations can hardly be translated into clinical practice as it stands. Data on NSAIDs' in vitro activity against planktonic bacteria and biofilms are not consistent (Riordan et al, 2011;Belfield et al, 2017;Abbas et al, 2020;Gerner et al, 2020;Leão et al, 2020). In addition, there is evidence showing the selection of resistant bacterial populations following exposure to NSAIDs (Cohen et al, 1993;Gustafson et al, 1999;Helal, 2012;Belfield et al, 2017;Verma et al, 2018).…”

Section: Introductionmentioning

confidence: 99%

“…2020;Wei et al, 2020 Diclofenac Riordan et al, 2011Yang et al, 2016;Abbas et al, 2020;Brilhante et al, 2020 IbuprofenYang et al, 2016;Shah et al, 2018;Dai et al, 2019;Oliveira et al, 2019 …”

unclassified

“…between 22.67 and 70%(Abbas et al, 2020). Diclofenac when tested against a S. aureus isolate demonstrated in vitro activity with a high MIC (2,000 µg/mL) and no detectable minimal bactericidal concentration (>2,000 µg/mL;Leão et al).…”

mentioning

confidence: 99%

See 4 more Smart Citations

Antimicrobial Activity of Non-steroidal Anti-inflammatory Drugs on Biofilm: Current Evidence and Potential for Drug Repurposing

Leme

Silva²

2021

Front. Microbiol.

View full text Add to dashboard Cite

It has been demonstrated that some non-steroidal anti-inflammatory drugs (NSAIDs), like acetylsalicylic acid, diclofenac, and ibuprofen, have anti-biofilm activity in concentrations found in human pharmacokinetic studies, which could fuel an interest in repurposing these well tolerated drugs as adjunctive therapies for biofilm-related infections. Here we sought to review the currently available data on the anti-biofilm activity of NSAIDs and its relevance in a clinical context. We performed a systematic literature review to identify the most commonly tested NSAIDs drugs in the last 5 years, the bacterial species that have demonstrated to be responsive to their actions, and the emergence of resistance to these molecules. We found that most studies investigating NSAIDs’ activity against biofilms were in vitro, and frequently tested non-clinical bacterial isolates, which may not adequately represent the bacterial populations that cause clinically-relevant biofilm-related infections. Furthermore, studies concerning NSAIDs and antibiotic resistance are scarce, with divergent outcomes. Although the potential to use NSAIDs to control biofilm-related infections seems to be an exciting avenue, there is a paucity of studies that tested these drugs using appropriate in vivo models of biofilm infections or in controlled human clinical trials to support their repurposing as anti-biofilm agents.

show abstract